"Epoprostenol" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY).
| Descriptor ID |
D011464
|
| MeSH Number(s) |
D10.251.355.255.550.550.500 D23.469.050.175.725.550.500
|
| Concept/Terms |
Epoprostenol- Epoprostenol
- PGI2
- Prostaglandin I2
- Prostacyclin
- Prostaglandin I(2)
- Epoprostanol
- PGX
Epoprostenol Sodium- Epoprostenol Sodium
- Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer
|
Below are MeSH descriptors whose meaning is more general than "Epoprostenol".
Below are MeSH descriptors whose meaning is more specific than "Epoprostenol".
This graph shows the total number of publications written about "Epoprostenol" by people in this website by year, and whether "Epoprostenol" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 |
| 1996 | 3 | 1 | 4 |
| 1997 | 3 | 0 | 3 |
| 1998 | 4 | 0 | 4 |
| 1999 | 1 | 2 | 3 |
| 2000 | 2 | 3 | 5 |
| 2001 | 5 | 0 | 5 |
| 2002 | 6 | 0 | 6 |
| 2003 | 7 | 0 | 7 |
| 2004 | 6 | 2 | 8 |
| 2005 | 4 | 5 | 9 |
| 2006 | 6 | 2 | 8 |
| 2007 | 3 | 2 | 5 |
| 2008 | 5 | 1 | 6 |
| 2009 | 4 | 6 | 10 |
| 2010 | 7 | 2 | 9 |
| 2011 | 1 | 0 | 1 |
| 2012 | 4 | 2 | 6 |
| 2013 | 8 | 1 | 9 |
| 2014 | 3 | 1 | 4 |
| 2015 | 1 | 1 | 2 |
| 2016 | 2 | 0 | 2 |
| 2017 | 4 | 2 | 6 |
| 2018 | 3 | 3 | 6 |
| 2019 | 2 | 0 | 2 |
| 2020 | 1 | 3 | 4 |
| 2021 | 4 | 1 | 5 |
| 2022 | 2 | 1 | 3 |
| 2023 | 0 | 2 | 2 |
| 2024 | 0 | 2 | 2 |
Below are the most recent publications written about "Epoprostenol" by people in Profiles.
-
Prostacyclin synthase deficiency exacerbates systemic inflammatory responses in lipopolysaccharide-induced septic shock in mice. Inflamm Res. 2024 Aug; 73(8):1349-1358.
-
Does early prostacyclin therapy decrease extracorporeal life support use in infants with congenital diaphragmatic hernia? J Perinatol. 2024 Apr; 44(4):594-597.
-
Tyvaso DPI: Drug-device characteristics and patient clinical considerations. Pulm Pharmacol Ther. 2023 Dec; 83:102266.
-
Parenteral treprostinil induction for rapid attainment of therapeutic doses of oral treprostinil. Respir Med. 2023 11; 218:107374.
-
Association Between Early Prostacyclin Therapy and Extracorporeal Life Support Use in Patients With Congenital Diaphragmatic Hernia. JAMA Pediatr. 2023 06 01; 177(6):582-589.
-
Trends in use of prostacyclin analogs for management of CDH-associated pulmonary hypertension. Pediatr Surg Int. 2022 Sep; 38(9):1241-1247.
-
The impact of nebulized epoprostenol and iloprost on hemoglobin oxygen affinity: an ex vivo experiment. Am J Physiol Lung Cell Mol Physiol. 2022 06 01; 322(6):L898-L903.
-
Inhaled Selective Pulmonary Vasodilator Use After Cardiac Surgery: Broader Insights From a Study Describing Significant Changes in Drug Utilization and Savings After Implementation of a Guideline Favoring Inhaled Epoprostenol. J Cardiothorac Vasc Anesth. 2022 05; 36(5):1350-1353.
-
Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension due to Parenchymal Lung Disease in the INCREASE Trial. Am J Respir Crit Care Med. 2022 01 15; 205(2):198-207.
-
Prostacyclin Synthase as an Ambivalent Regulator of Inflammatory Reactions. Biol Pharm Bull. 2022; 45(8):979-984.